(Q36115896)

12 August 2017

Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation (English)

1 reference

12 August 2017

1 reference

Emig R

1

1 reference

12 August 2017

Magener A

2

1 reference

12 August 2017

Ehemann V

3

1 reference

12 August 2017

Meyer A

4

1 reference

12 August 2017

Stilgenbauer F

5

1 reference

12 August 2017

Volkmann M

6

1 reference

12 August 2017

Wallwiener D

7

1 reference

12 August 2017

Sinn HP

8

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

78

1 reference

12 August 2017

1661-1668

1 reference

12 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.739

12 August 2017

0 references

cites work

High frequency of aberrant p16(INK4A) expression in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Molecular characterization of the retinoblastoma susceptibility gene

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

A cell cycle regulator potentially involved in genesis of many tumor types

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

DNA Cytometry Consensus Conference. DNA flow cytometry and breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Mutations and altered expression of p16INK4 in human cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

G1 phase progression: cycling on cue

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Mutations in the p53 gene occur in diverse human tumour types

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Cancer. p53, guardian of the genome

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

p16 inhibition of transformed and primary squamous epithelial cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Analysis of p16 gene deletion and point mutation in breast carcinoma

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Dislocation of mandibular condyle into middle cranial fossa

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

p53 quantitative immunocytochemical analysis in breast carcinomas.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063248

[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]

23 September 2018

1 reference

12 December 2020

DNA-Zytometrie beim Mammakarzinom

1 reference

12 December 2020

Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer

1 reference

12 December 2020

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer

1 reference

12 December 2020

Overexpression of p53 and prognosis in breast cancer

1 reference

12 December 2020

p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation

1 reference

12 December 2020

p21 inhibits cyclin shock

1 reference

12 December 2020

Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas

1 reference

12 December 2020

Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1

1 reference

12 December 2020

Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression

1 reference

12 December 2020

Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers

1 reference

12 December 2020

Novel germline p16 mutation in familial malignant melanoma in southern Sweden

1 reference

12 December 2020

High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.739

1 reference

12 August 2017

1 reference

12 August 2017

1 reference